Zejula Euroopan unioni - suomi - EMA (European Medicines Agency)

zejula

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - antineoplastiset aineet - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

Akeega Euroopan unioni - suomi - EMA (European Medicines Agency)

akeega

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - eturauhasen kasvaimet, kastraatio-resistentin - antineoplastiset aineet - treatment of adult patients with prostate cancer.

Lynparza Euroopan unioni - suomi - EMA (European Medicines Agency)

lynparza

astrazeneca ab - olaparib - munasarjojen kasvaimet - antineoplastiset aineet - munasarjojen cancerlynparza on tarkoitettu monoterapiana:huolto aikuisille potilaille, joilla on pitkälle edennyt (figo vaiheet iii ja iv) brca1/2-mutaation (ituradan ja/tai somaattisten) korkea-asteen epiteelin munasarjojen, munanjohtimien tai ensisijainen vatsakalvon syöpä, jotka ovat vaste (täydellinen tai osittainen) jälkeen ensilinjan platinapohjaisen kemoterapian. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 ja 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. potilaita on aikaisemmin hoidettu antrasykliineillä ja taxane in (neo)adjuvantti-tai metastasoitunut asetus, ellei potilaat eivät sovellu näihin hoitoihin (ks. kohta 5. potilaat, joilla on hormoni-reseptori (hr)-positiivinen rintasyöpä pitäisi myös olla edennyt tai sen jälkeen ennen hormonaalisen hoidon, tai katsotaan sopimattomaksi hormonaalisen hoidon. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

LYNPARZA 100 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

lynparza 100 mg tabletti, kalvopäällysteinen

astrazeneca ab - olaparibum - tabletti, kalvopäällysteinen - 100 mg - olaparibi

LYNPARZA 150 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

lynparza 150 mg tabletti, kalvopäällysteinen

astrazeneca ab - olaparibum - tabletti, kalvopäällysteinen - 150 mg - olaparibi

DIFLUCAN 2 mg/ml infuusioneste, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

diflucan 2 mg/ml infuusioneste, liuos

pfizer oy pfizer oy - fluconazolum - infuusioneste, liuos - 2 mg/ml - flukonatsoli

Fluconazol Fresenius Kabi 2 mg/ml infuusioneste, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

fluconazol fresenius kabi 2 mg/ml infuusioneste, liuos

fresenius kabi ab - fluconazole - infuusioneste, liuos - 2 mg/ml - flukonatsoli

CANESORAL 150 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

canesoral 150 mg kapseli, kova

bayer oy - fluconazolum - kapseli, kova - 150 mg - flukonatsoli

METFORMIN ORION 500 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

metformin orion 500 mg depottabletti

orion corporation - metformini hydrochloridum - depottabletti - 500 mg - metformiini

METFORMIN ORION 750 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

metformin orion 750 mg depottabletti

orion corporation - metformini hydrochloridum - depottabletti - 750 mg - metformiini